CHMP issues positive scientific opinion for bamlanivimab alone and in combination with etesevimab for treatment of confirmed COVID-19

Approval based on results from BLAZE-1 study which showed bamlanivimab (B) reduced viral load, symptoms and hospitalizations by 70%, and B+ etesevimab reduced risk of hospitalizations and death by 70% in pts aged >12 years who do not require oxygen and at risk of severe COVID-19.

Source:

Biospace Inc.